Shares of GlaxoSmithKline PLC (NYSE:GSK) have been given an average recommendation of “Hold” by the nineteen ratings firms that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $43.50.

A number of research analysts have recently commented on GSK shares. Zacks Investment Research raised shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research report on Wednesday, October 18th. Morgan Stanley cut shares of GlaxoSmithKline PLC from an “equal weight” rating to an “underweight” rating in a research report on Friday, September 8th. Argus reissued a “buy” rating and set a $50.00 target price on shares of GlaxoSmithKline PLC in a research report on Thursday, August 31st. TheStreet raised shares of GlaxoSmithKline PLC from a “c+” rating to a “b” rating in a research report on Wednesday, October 25th. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Tuesday, October 24th.

In other GlaxoSmithKline PLC news, major shareholder Plc Glaxosmithkline bought 428,571 shares of the stock in a transaction on Monday, November 6th. The stock was purchased at an average price of $14.00 per share, for a total transaction of $5,999,994.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in GSK. Proficio Capital Partners LLC increased its stake in GlaxoSmithKline PLC by 16.1% during the second quarter. Proficio Capital Partners LLC now owns 3,301 shares of the pharmaceutical company’s stock valued at $135,000 after purchasing an additional 457 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its stake in GlaxoSmithKline PLC by 1.9% during the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company’s stock valued at $137,000 after purchasing an additional 64 shares during the last quarter. Wealthcare Advisory Partners LLC increased its stake in GlaxoSmithKline PLC by 1,982.8% during the third quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock valued at $143,000 after purchasing an additional 3,351 shares during the last quarter. FTB Advisors Inc. increased its stake in GlaxoSmithKline PLC by 16.9% during the second quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock valued at $146,000 after purchasing an additional 539 shares during the last quarter. Finally, Quadrant Capital Group LLC increased its stake in GlaxoSmithKline PLC by 3.5% during the second quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after purchasing an additional 148 shares during the last quarter. Hedge funds and other institutional investors own 9.32% of the company’s stock.

GlaxoSmithKline PLC (NYSE:GSK) traded down $0.10 during midday trading on Thursday, hitting $34.88. 4,245,700 shares of the stock were exchanged, compared to its average volume of 3,440,653. GlaxoSmithKline PLC has a twelve month low of $34.72 and a twelve month high of $44.53. The company has a current ratio of 0.64, a quick ratio of 0.44 and a debt-to-equity ratio of 2.96. The firm has a market capitalization of $85,410.00, a PE ratio of 12.40, a P/E/G ratio of 1.94 and a beta of 1.00.

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Investors of record on Friday, November 10th will be issued a $0.5037 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.49. This represents a $2.01 annualized dividend and a yield of 5.78%. GlaxoSmithKline PLC’s dividend payout ratio is currently 159.20%.

ILLEGAL ACTIVITY WARNING: “GlaxoSmithKline PLC (GSK) Given Average Recommendation of “Hold” by Brokerages” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/16/glaxosmithkline-plc-gsk-given-average-recommendation-of-hold-by-brokerages-2.html.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.